Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €88.55 EUR
Change Today -1.18 / -1.31%
Volume 505.0
S3F On Other Exchanges
Symbol
Exchange
S3F is not on other exchanges.
As of 10:28 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

santhera pharmaceuticals-reg (S3F) Snapshot

Open
€87.84
Previous Close
€89.72
Day High
€88.55
Day Low
€87.24
52 Week High
02/3/15 - €113.80
52 Week Low
08/8/14 - €47.00
Market Cap
434.9M
Average Volume 10 Days
123.1
EPS TTM
--
Shares Outstanding
4.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SANTHERA PHARMACEUTICALS-REG (S3F)

Related News

No related news articles were found.

santhera pharmaceuticals-reg (S3F) Related Businessweek News

No Related Businessweek News Found

santhera pharmaceuticals-reg (S3F) Details

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases in the areas of various orphan and niche indications primarily in North America and the European Union. It offers Raxone/Catena for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) and Duchenne Muscular Dystrophy (DMD). The company also develops Raxone/Catena for treating patients with primary progressive Multiple Sclerosis. It also develops omigapil that is in Phase I trial for the treatment of Congenital Muscular Dystrophies. The company has a collaboration agreement with the US patient advocacy organization for a survey- based benefit/risk evaluation in DMD. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Liestal, Switzerland.

14.7 Employees
Last Reported Date: 04/14/15
Founded in 2004

santhera pharmaceuticals-reg (S3F) Top Compensated Officers

Chief Executive Officer and Head of the Execu...
Total Annual Compensation: SFr.426.9K
Compensation as of Fiscal Year 2014.

santhera pharmaceuticals-reg (S3F) Key Developments

Santhera Pharmaceuticals Holding AG Announces First Patient Dosing with Omigapil in Congenital Muscular Dystrophy (CMD) and Full Patient Recruitment of CALLISTO Study

Santhera Pharmaceuticals Holding AG announced that the first patient in the CALLISTO Phase I study assessing the pharmacokinetics, safety and tolerability of oral omigapil in patients with Congenital Muscular Dystrophy (CMD) has been dosed and all participating patients have been recruited. This study, which is being conducted at the US National Institutes of Health (NIH), will also evaluate the feasibility of conducting disease-relevant clinical assessments that could be used as endpoints in future efficacy trials in pediatric and adolescent CMD patients. The study is being conducted at the NIH's National Institute of Neurological Disorders and Stroke (NINDS) in Bethesda, Maryland, and will evaluate use of the compound in 20 ambulatory and non-ambulatory patients aged 5 to 16 years affected by either Ullrich or MDC1A subtypes of CMD. All patients have been selected, pre-screened and randomly assigned to one of the three study cohorts that are starting sequentially with ascending doses of omigapil. Following a 4-week vehicle run-in phase, each patient will receive one of three doses of omigapil (0.02, 0.08 or 0.2 mg/kg/day) for 12 weeks, during which period the pharmacokinetics of omigapil will be assessed as well as the patients' respiratory function, muscle strength and motor function. To ensure the collection of as much information as possible from both subtypes of CMD, Ullrich or MDC1A, all patients have been identified and randomized prior to the first dosing. The first patient received the starting dose of 0.02 mg/kg/day, applied in a new liquid formulation developed by Santhera for this patient population. Only after an independent data and safety monitoring board (DSMB) has assessed the pharmacokinetic and safety data in each completed cohort, dosing in subsequent cohorts will follow at ascending doses. Due to the staggered dosing of patients, the study is expected to run until the end of 2016.

Santhera Pharmaceuticals Holding AG Appoints as CFO and Member of the Executive Management Team

Santhera Pharmaceuticals announced the appointment of Christoph Rentsch as Chief Financial Officer. With effect from July 1, 2015, the Santhera Board of Directors appoints Christoph Rentsch as CFO and member of the Executive Management Team headed by Chief Executive Officer Thomas Meier, PhD. Christoph Rentsch started his career in investment banking at Credit Suisse. Subsequently, he worked for Lonza both in Switzerland and the US. Thereafter he joined Roche as Head of Group Funding and Capital Markets for several years before he became partner of Caperis Ltd, an investment advisory and management firm. Since 2010 he served as CFO of privately-held Polyphor, where he led several financing rounds and supported the company in key stages of its development. Christoph Rentsch holds a degree in economics and business administration from the University of Applied Sciences, Basel.

Santhera Pharmaceuticals Approves Amendments to its Articles of Association

Santhera Pharmaceuticals held its AGM on May 11, 2015 and shareholders approved the corresponding amendments of the articles of association in relation to corporate governance and remuneration policies for the board of directors and executive management.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
S3F:GR €88.55 EUR -1.18

S3F Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for S3F.
View Industry Companies
 

Industry Analysis

S3F

Industry Average

Valuation S3F Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 187.0x
Price/Book 28.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 182.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANTHERA PHARMACEUTICALS-REG, please visit www.santhera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.